A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma

Abstract

We consider the qPCR to be an accurate method for assessing samples with low amounts of malignant cells.

Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial

“…Median days of grade 3 or 4 neutropenia or thrombocytopenia were 7 (2-20) and 8 (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17). Median mobilization days, CD34 þ cells/kg and total leukaphereses were 16 (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30), 12.1 million (2.6-52.8), and 2 (1)(2)(3)(4)(5) respectively. Four patients (12.5 %) failed to achieve the target of 4 million CD34 þ cells/kg in five leukaphereses.…”

“…[13][14][15] Furthermore, ample evidence exists to support the view that patients receiving autografts with increasing amounts of tumor cell contamination relapse frequently and have shorter remission durations, although this could reflect tumor burden at the time of HCT. [16][17][18][19][20][21][22][23] Melphalan is the most effective single agent in the treatment of myeloma; its chronic use can be toxic to stem cells and can cause treatment-related leukemia. 24,25 Perhaps, that is why it has not commonly been used for stem cell mobilization.…”

“…Of these, two had sufficient cells collected with a sixth leukapheresis and two were collected again with G-CSF mobilization (all four subsequently underwent SCT). The median number of days until initiation of leukapheresis was 16 (range [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30]. The median number of CD34 þ cells/kg collected was 12.1 million  10 6 (2.6-52.8).…”

Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation

“…17,18 Briefly, cDNA was synthesized using Oligo d(T) 16 and 2 g of total RNA from a BM sample taken prior to HDT. Reverse-transcription was performed with Moloney murine leukemia virus reverse transcriptase (Perkin Elmer, Weiterstadt, Germany) at 42°C for 15 min.…”

Effects of the glucolipid synthase inhibitor, P4, on functional and phenotypic parameters of murine myeloma cells

“…Although new treatment regimens incorporating bone marrow transplantation achieve 5 times higher complete remission rates and prolonged overall survival compared to conventional therapy, i.e. melphalan and prednisolone, relapse due to residual disease is inevitable, with a median survival of 36 months (Cremer et al, 1997). The effects of Effects of the glucolipid synthase inhibitor, P4, on functional and phenotypic parameters of murine myeloma cells P4 on cell growth, metabolism, clonogenicity and antigen expression were determined in vitro prior to conducting in vivo studies addressing the therapeutic efficacy and immunization potential of this inhibitor in mice.…”